Arbutus Biopharma (ABUS) Cash from Investing Activities (2013 - 2026)

Arbutus Biopharma has disclosed Cash from Investing Activities across 14 years of filings, most recently posting $2.2 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $2.2 million, down 80.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (down 71.55% YoY), and the FY2025 annual result was $15.6 million, down 32.11% from the prior year.
• Cash from Investing Activities came in at $2.2 million for Q1 2026 at Arbutus Biopharma, up from -$1.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $22.2 million in Q4 2023 to a low of -$60.1 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $9.8 million (2024), against an average of $974000.0.
• Across the five-year window, Cash from Investing Activities tumbled 429.6% in 2022 and jumped 582.1% in 2024, its largest moves.
• Arbutus Biopharma's Cash from Investing Activities stood at $12.7 million in 2022, then surged by 75.25% to $22.2 million in 2023, then sank by 39.66% to $13.4 million in 2024, then tumbled by 110.15% to -$1.4 million in 2025, then surged by 261.57% to $2.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $2.2 million (Q1 2026), -$1.4 million (Q4 2025), and -$10.0 million (Q3 2025), per Business Quant data.